{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:32:01Z","timestamp":1793320321452,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Mission Boost Award"],"award-info":[{"award-number":["Mission Boost Award"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS126187"],"award-info":[{"award-number":["R01-NS126187"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["R01-DC020724"],"award-info":[{"award-number":["R01-DC020724"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0222"],"award-info":[{"award-number":["W81XWH-20-1-0222"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,11,30]]},"DOI":"10.1038\/s41416-024-02863-9","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T09:01:37Z","timestamp":1728118897000},"page":"1683-1693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer"],"prefix":"10.1038","volume":"131","author":[{"given":"Yao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor L.","family":"Gomes dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinji","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-8699","authenticated-orcid":false,"given":"Bo R.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-3548","authenticated-orcid":false,"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-183X","authenticated-orcid":false,"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"key":"2863_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2863_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9:851\u20139.","journal-title":"JAMA Oncol"},{"key":"2863_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","volume":"3","author":"SL Gaillard","year":"2016","unstructured":"Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.","journal-title":"Gynecol Oncol Res Pract"},{"key":"2863_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clinthera.2018.01.005","volume":"40","author":"T Castellano","year":"2018","unstructured":"Castellano T, Moore KN, Holman LL. An overview of immune checkpoint inhibitors in gynecologic cancers. Clin Ther. 2018;40:372\u201388.","journal-title":"Clin Ther"},{"key":"2863_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.molimm.2008.08.266","volume":"46","author":"SP Bak","year":"2008","unstructured":"Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol. 2008;46:258\u201368.","journal-title":"Mol Immunol"},{"key":"2863_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"2863_CR7","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","volume":"11","author":"D Wolf","year":"2005","unstructured":"Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326\u201331.","journal-title":"Clin Cancer Res"},{"key":"2863_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1593\/tlo.12265","volume":"5","author":"D Samrao","year":"2012","unstructured":"Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 2012;5:469\u201374.","journal-title":"Transl Oncol"},{"key":"2863_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.celrep.2019.12.034","volume":"30","author":"E Maniati","year":"2020","unstructured":"Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, et al. Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. Cell Rep. 2020;30:525\u201340.","journal-title":"Cell Rep"},{"key":"2863_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nnano.2012.45","volume":"7","author":"VP Chauhan","year":"2012","unstructured":"Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383\u20138.","journal-title":"Nat Nanotechnol"},{"key":"2863_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","volume":"16","author":"RK Jain","year":"2014","unstructured":"Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng. 2014;16:321\u201346.","journal-title":"Annu Rev Biomed Eng"},{"key":"2863_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4:292\u2013319.","journal-title":"Trends Cancer"},{"key":"2863_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2016.07.032","volume":"166","author":"D Clever","year":"2016","unstructured":"Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell. 2016;166:1117\u201331.","journal-title":"Cell"},{"key":"2863_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Rev Clin Oncol. 2018;15:325\u201340.","journal-title":"Nature Rev Clin Oncol"},{"key":"2863_CR15","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109:17561\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2863_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"key":"2863_CR17","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1158\/1078-0432.CCR-07-0374","volume":"13","author":"EA Manning","year":"2007","unstructured":"Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13:3951\u20139.","journal-title":"Clin Cancer Res"},{"key":"2863_CR18","doi-asserted-by":"publisher","first-page":"a027094","DOI":"10.1101\/cshperspect.a027094","volume":"6","author":"JD Martin","year":"2016","unstructured":"Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK. Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity. Cold Spring Harb Perspect Med. 2016;6:a027094.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2863_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372.","journal-title":"Cancer Cell"},{"key":"2863_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1126\/science.aaw7875","volume":"365","author":"LL Munn","year":"2019","unstructured":"Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science. 2019;365:544\u20135.","journal-title":"Science"},{"key":"2863_CR21","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516\u201327.","journal-title":"Nat Commun"},{"key":"2863_CR22","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA. 2011;108:2909\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2863_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9:eaan5616.","journal-title":"Sci Transl Med"},{"key":"2863_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/1078-0432.CCR-21-2105","volume":"28","author":"DP Regan","year":"2022","unstructured":"Regan DP, Chow L, Das S, Haines L, Palmer E, Kurihara JN, et al. Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma. Clin Cancer Res. 2022;28:662\u201376.","journal-title":"Clin Cancer Res"},{"key":"2863_CR25","doi-asserted-by":"publisher","unstructured":"Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci USA. 2019:pii:201818357. https:\/\/doi.org\/10.1073\/pnas.1818357116.","DOI":"10.1073\/pnas.1818357116"},{"key":"2863_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3389\/fphar.2018.00878","volume":"9","author":"X Cen","year":"2018","unstructured":"Cen X, Liu S, Cheng K. The role of toll-like receptor in inflammation and tumor immunity. Front Pharmacol. 2018;9:878.","journal-title":"Front Pharmacol"},{"key":"2863_CR27","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/cancers12071939","volume":"12","author":"A Bradbury","year":"2020","unstructured":"Bradbury A, O\u2019Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting. Cancers. 2020;12:1939.","journal-title":"Cancers"},{"key":"2863_CR28","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31:e439\u201342.","journal-title":"J Clin Oncol"},{"key":"2863_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747\u201352.","journal-title":"Nat Med"},{"key":"2863_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577\u201381.","journal-title":"Nature"},{"key":"2863_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cellimm.2018.06.008","volume":"331","author":"DD Zhdanov","year":"2018","unstructured":"Zhdanov DD, Gladilina YA, Pokrovsky VS, Grishin DV, Grachev VA, Orlova VS, et al. Murine regulatory T cells induce death of effector T, B, and NK lymphocytes through a contact-independent mechanism involving telomerase suppression and telomere-associated senescence. Cell Immunol. 2018;331:146\u201360.","journal-title":"Cell Immunol"},{"key":"2863_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctrv.2017.08.012","volume":"60","author":"JAL Liefers-Visser","year":"2017","unstructured":"Liefers-Visser JAL, Meijering RAM, Reyners AKL, van der Zee AGJ, de Jong S. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat Rev. 2017;60:90\u20139.","journal-title":"Cancer Treat Rev"},{"key":"2863_CR33","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41388-017-0115-x","volume":"37","author":"L Ireland","year":"2018","unstructured":"Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, et al. Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene. 2018;37:2022\u201336.","journal-title":"Oncogene"},{"key":"2863_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4161\/cbt.2.6.678","volume":"2","author":"A Grimberg","year":"2003","unstructured":"Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2003;2:630\u20135.","journal-title":"Cancer Biol Ther"},{"key":"2863_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fendo.2018.00297","volume":"9","author":"MA Yahya","year":"2018","unstructured":"Yahya MA, Sharon SM, Hantisteanu S, Hallak M, Bruchim I. The role of the insulin-like growth factor 1 pathway in immune tumor microenvironment and its clinical ramifications in gynecologic malignancies. Front Endocrinol. 2018;9:297.","journal-title":"Front Endocrinol"},{"key":"2863_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22:1034\u201346.","journal-title":"Lancet Oncol"},{"key":"2863_CR37","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39:3671\u201381.","journal-title":"J Clin Oncol"},{"key":"2863_CR38","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72:1070\u201380.","journal-title":"Cancer Res"},{"key":"2863_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095.","journal-title":"Nat Commun"},{"key":"2863_CR40","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"AK Palucka","year":"2016","unstructured":"Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233\u201347.","journal-title":"Cell"},{"key":"2863_CR41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080\u20137.","journal-title":"Ann Oncol"},{"key":"2863_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ceb.2015.06.006","volume":"36","author":"R Hallmann","year":"2015","unstructured":"Hallmann R, Zhang X, Di Russo J, Li L, Song J, Hannocks MJ, et al. The regulation of immune cell trafficking by the extracellular matrix. Curr Opin Cell Biol. 2015;36:54\u201361.","journal-title":"Curr Opin Cell Biol"},{"key":"2863_CR43","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1158\/0008-5472.CAN-06-1495","volume":"66","author":"D Xing","year":"2006","unstructured":"Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 2006;66:8949\u201353.","journal-title":"Cancer Res"},{"key":"2863_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585\u201391.","journal-title":"Carcinogenesis"},{"key":"2863_CR45","first-page":"5107","volume":"51","author":"D Yee","year":"1991","unstructured":"Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991;51:5107\u201312.","journal-title":"Cancer Res"},{"key":"2863_CR46","first-page":"756","volume":"69","author":"M Resnicoff","year":"1993","unstructured":"Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest. 1993;69:756\u201360.","journal-title":"Lab Invest"},{"key":"2863_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0046-8177(03)00291-0","volume":"34","author":"A Ouban","year":"2003","unstructured":"Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34:803\u20138.","journal-title":"Hum Pathol"},{"key":"2863_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/14728222.2013.749863","volume":"17","author":"I Bruchim","year":"2013","unstructured":"Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets. 2013;17:307\u201320.","journal-title":"Expert Opin Ther Targets"},{"key":"2863_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0065-230X(08)60354-1","volume":"68","author":"H Werner","year":"1996","unstructured":"Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 1996;68:183\u2013223.","journal-title":"Adv Cancer Res"},{"key":"2863_CR50","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1210\/en.2005-0888","volume":"147","author":"Y Ma","year":"2006","unstructured":"Ma Y, Zhang L, Peng T, Cheng J, Taneja S, Zhang J, et al. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology. 2006;147:1256\u201363.","journal-title":"Endocrinology"},{"key":"2863_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1139\/y02-154","volume":"81","author":"GE Haddad","year":"2003","unstructured":"Haddad GE, Blackwell K, Bikhazi A. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist. Can J Physiol Pharmacol. 2003;81:142\u20139.","journal-title":"Can J Physiol Pharmacol"},{"key":"2863_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2015.00025","volume":"6","author":"A Pickard","year":"2015","unstructured":"Pickard A, McCance DJ. IGF-binding protein 2 - oncogene or tumor suppressor? Front Endocrinol. 2015;6:25.","journal-title":"Front Endocrinol"},{"key":"2863_CR53","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","volume":"39","author":"T Li","year":"2020","unstructured":"Li T, Forbes ME, Fuller GN, Li J, Yang X, Zhang W. IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene. 2020;39:2243\u201357.","journal-title":"Oncogene"},{"key":"2863_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abj5879","volume":"15","author":"LL Remsing Rix","year":"2022","unstructured":"Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, et al. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022;15:eabj5879.","journal-title":"Sci Signal"},{"key":"2863_CR55","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-0672-2","volume":"10","author":"S Baron-Hay","year":"2004","unstructured":"Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 2004;10:1796\u2013806.","journal-title":"Clin Cancer Res"},{"key":"2863_CR56","first-page":"325","volume":"8","author":"DJ Beech","year":"2001","unstructured":"Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep. 2001;8:325\u20139.","journal-title":"Oncol Rep"},{"key":"2863_CR57","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/sj.onc.1206186","volume":"22","author":"CL Mamay","year":"2003","unstructured":"Mamay CL, Mingo-Sion AM, Wolf DM, Molina MD, Van Den Berg CL. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene. 2003;22:602\u201314.","journal-title":"Oncogene"},{"key":"2863_CR58","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"2863_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s43018-019-0007-9","volume":"1","author":"D Ajona","year":"2020","unstructured":"Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat Cancer. 2020;1:75\u201385.","journal-title":"Nat Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02863-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:05:22Z","timestamp":1731463522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02863-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11,30]]}},"alternative-id":["2863"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02863-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K.J. received consultant fees from Cur, Elpis, Innocoll, SPARC, and SynDevRx; owns equity in Accurius, Enlight, and SynDevRx; is on the Board of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund; and received research grants from Boehringer Ingelheim and Sanofi. No funding or reagents from these companies were used in this study. B.R.R. reports serving on the advisory board for VincenTech which has no direct connection to the current research. The other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}